Oromandibular Distoni: Etiyolojisi, Tanı ve Tedavi Yöntemleri

Comella, C.L. Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon 2018, 147, 96–99.

Scorr, L.M.; Factor, S.A.; Parra, S.P.; Kaye, R.; Paniello, R.C.; Norris, S.A.; Perlmutter, J.S.; Bäumer, T.; Usnich, T.; Berman, B.D.; et al. Oromandibular dystonia: A clinical examination of 2020 cases. Front. Neurol. 2021, 12, 700714.

Yoshida K. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System. Toxins (Basel). 2022 Apr 14;14(4):282. doi: 10.3390/toxins14040282

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord 2013; 28:863 73.

Jinnah HA. Diagnosis and treatment of dystonia. Neurol Clin 2015; 33:77-100.

Hallet M. Neurophysiology of dystonia: The role of inhibition. Neurobiol Dis 2011; 42:177-84.

Britton D, Alty JE, Mannion CJ. Oromandibular dystonia: a diagnosis not to miss. Br J Oral Maxillofac Surg. 2020 Jun;58(5):520-524. doi: 10.1016/j.bjoms.2020.02.018. Epub 2020 Mar 3.

Colosimo C.; Berardelli A. Clinical phenomenology of dystonia. Int. Rev. Neurobiol. 2011, 98, 509–524

Teive HA, Kluppel LE, Munhoz RP, Becker N, Müller PR, Werneck LC. Jawopening oromandibular dystonia secondary to Wilson’s disease treated with botulinum toxin type A. Arq Neuropsiquiatr 2012; 70:407-9.

Teemul TA, Patel R, Kanatas A, Carter LM. Management of oromandibular dystonia with botulinum A toxin: A series of cases. Br J Oral Maxillofac Surg 2016; 54:1080-4.

Colosimo S, Fabbrini et al. Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 2010; 17(Suppl 1):15–21.

Fabbrini G, Defazio G, Colosimo C et al Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment. Nat Clin Pract Neurol 2009; 5:93–105.

Meige H. Les convulsions de la face: Une forme clinique de convulsion faciale, bilatérale et médiane. Rev. Neurol. 1910, 10, 437–443.

Maezawa H, Hirata M, Yoshida K. Neurophysiological Basis of Deep Brain Stimulation and Botulinum Neurotoxin Injection for Treating Oromandibular Dystonia. Toxins (Basel). 2022 Nov 2;14(11):751.

Manzo N, Ginatempo F, Belvisi D, Defazio G, Conte A, Deriu F, Berardelli A. Pathophysiological mechanisms of oromandibular dystonia. Clin Neurophysiol. 2022 Feb; 134:73-80. doi: 10.1016/j.clinph.2021.11.075. Epub 2021 Dec 21

Wang L, Chen Y, Hu B, et al. Late-onset primary dystonia in Zhejiang province of China: a service-based epidemiological study. Neurol Sci 2016; 37:111–6.

Pekmezovi´c T, Ivanovi´c N, Svetel M, et al. Prevalence of primary late-onset focal dystonia in the Belgrade population. Mov Disord 2003; 18:1389–92.

Asgeirsson H, Jakobsson F, Hjaltason H, et al. Prevalence study of primary dystonia in Iceland. Mov Disord 2006; 21:293–8.

Ortiz R, Scheperjans F, Mertsalmi T, et al. The prevalence of adult-onset isolated dystonia in Finland 2007-2016. PLoS One 2018; 13:e0207729.6

Sex related influences on the frequency and age of onset of primary dystonia. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group. Neurology 1999;53:1871 3. doi: 10.1212/wnl.53.8.1871

Defazio G, Jankovic J, Giel JL, et al. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (NY) 2013;3, pii:tre-03-193-4374-2.

Madeo G, Pisani A. Pathophysiology of dystonia. Handb Behav Neurosci 2016;24:929–50.

Waln, O.; Jankovic, J. An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet. Mov. 2013,3, 1–11.

Savitt, D.; Jankovic, J. Tardive syndromes. J. Neurol. Sci. 2018, 389, 35–42.

Skármeta, N.P.; Espinoza-Mellado, P.; Chana, P. Orofacial dystonia and other oromandibular movement disorders. In Dystonia- Different Prospects; Rizk, T.M.G., Ed.; IntechOpen: London, UK, 2018; Available online: https://www.intechopen.com/chapters/ 62475 (accessed on 31 August 2022).

Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155:1521–8.

Rommel N, Rohleder NH, Koerdt S, et al. Sympathomimetic effects of chronic methamphetamine abuse on oral health: a cross-sectional study. BMC Oral Health 2016; 16:59.

Akin A, Yilmaz R, Selcuk F, Akbostancı MC. Sudden onset of oromandibular dystonia after cerebellar stroke. Tremor Other Hyperkinet Mov (N Y). 2014 Oct 28;4:262. doi: 10.7916/D8C24TN3. eCollection 2014

Waln O, LeDoux MS. Delayed-onset oromandibular dystonia after a cerebellar hemorrhagic stroke. Parkinsonism Relat Disord. 2010 Nov;16(9):623-5. doi: 10.1016/j.parkreldis.2010.07.010.

Lo SE, Rosengart AJ, Novakovic RL, Kang UJ, Shah DN, Khan MA, Dalvi A, Goldenberg FD, Macdonald RL, Frank JI. Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients. Neurocrit Care. 2005;3(2):139-45. doi: 10.1385/NCC:3:2:139

Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):186-90. doi: 10.1136/jnnp.68.2.186.

Dietrichs E, Heier MS, Nakstad PH. Jaw opening dystonia presumably caused by a pontine lesion. Mov Disord 2000; 15:1026 8.

Tarabzouni S, AlKhairallah T. Isolated neurological manifestation in silent celiac disease. J Mov Disord 2017; 10:105 7.

Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N. Orofacial dystonia related to Sjogren’s syndrome. Clin Rheumatol 2007; 26:1779 81.

Wu K, Christodoulou L, Siddiqui A, D’Cruz D, Andrews T. Bilateral reversible basal ganglia changes associated with dystonia and hemifacial spasms in central nervous system lupus. Quant Imaging Med Surg 2015; 5:928 9.

Raoofi S, Khorshidi H, Najafi M. Etiology, diagnosis and management of oromandibular dystonia: An update for stomatologists. J Dent (Shiraz) 2017; 18:73 81.

Schrag A, Bhatia KP, Quinn NP, Marsden CD. Atypical and typical cranial dystonia following dental procedures. Mov Disord 1999; 14:492 6.

Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 1998; 65:722 8.

Saraf U, Chandarana M, Divya KP, Krishnan S. Oromandibular Dystonia - A Systematic Review. Ann Indian Acad Neurol. 2022 Jan-Feb;25(1):26-34.

Sakar O, Matur Z, Mumcu Z, Sesen P, Oge E. Multidisciplinary management of a partially edentulous patient with oromandibular dystonia: A clinical report. J Prosthet Dent. 2018

Clark GT, Ram S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am 2016; 28:397 407.

Skármeta NP, Espinoza Mellado P, Chana P. Orofacial dystonia and other oromandibular movement disorders. In: Rizk TMG, editor. Dystonia. Rijeka: IntechOpen; 2018.

Frucht SJ, Fahn S, Greene PE, O’Brien C, Gelb M, Truong DD, et al. The natural history of embouchure dystonia. Mov Disord 2001; 16:899 906.

Hartmann A, Pogarell O, Oertel WH. Secondary dystonias. J Neurol1998; 245:511–8.

Bakke M, Larsen BM, Dalager T, et al. Oromandibular dystonia—functional and clinical characteristics: a report on 21cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:e21–6.

Gonzalez Alegre P, Schneider RL, Hoffman H. Clinical, etiological, and therapeutic features of jaw opening and jaw closing oromandibular dystonias: A decade of experience at a single treatment center. Tremor Other Hyperkinet Mov (N Y) 2014;4:231.

Louis ED. Essential tremor: a nuanced approach to the clinical features. Pract Neurol 2019;19:389–98.

Blanchet PJ, Rompré PH, Lavigne GJ, et al. Oral dyskinesia: a clinical overview. Int J Prosthodont 2005; 18:10–9.

Watts E, Sangani I, Crawford F, et al. The role of a dentist in managing patients with dystonia. Dent Update 2013; 40:846–8.20.

Macerollo A, Superbo M, Gigante AF, Livrea P, Defazio G (2015) Diagnostic delay in adult-onset dystonia: data from an Italian movement disorder center. J Clin Neurosci 22:608–610. https://doi.org/ 10.1016/j.jocn.2014.09.014

Powell AT, Bidewell JW, Walker AC (1995) Diagnosing idiopathic dystonia: must it take so long? Aust Health Rev 18:120–131

Jog M, Chouinard S, Hobson D, Grimes D, Chen R, Bhogal M, Simonyi S (2011) Causes for treatment delays in dystonia and hemifacial spasm: a Canadian survey. Can J Neurol Sci 38:704–711

Tiderington E, Goodman EM, Rosen AR, Hapner ER, Johns MM 3rd, Evatt ML, Freeman A, Factor S, Jinnah HA (2013) How long does it take to diagnose cervical dystonia? J Neurol Sci 335:72–74. https://doi.org/10.1016/j.jns.2013.08.028

Bertram KL, Williams DR (2016) Delays to the diagnosis of cervical dystonia. J Clin Neurosci 25:62–64. https://doi.org/10.1016/j. jocn.2015.05.054

Yoshida K. Oromandibular dystonia screening questionnaire for differential diagnosis. Clin Oral Investig. 2019 Jan;23(1):405-411. doi: 10.1007/s00784-018-2449-3. Epub 2018 May 2

Thenganatt MA, Jankovic J (2015) Psychogenic movement disorders. Neurol Clin 33:205–224. https://doi.org/10.1016/j. ncl.2014.09.013

Yoshida K. Sensory trick splint as a multimodal therapy for oromandibular dystonia. J Prosthodont Res 2018; 62:239–244. https://doi.org/10.1016/j.jpor.2017.09.004

Donaldson I, Marsden CD, Schneider SA, Bhatia KP. Marsden’s Book of Movement Disorders. Idiopathic (primary) cranial dystonias: Oxford University Press; 2012.

Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol 2016;36:84 91.

Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope 2013; 123: 3078–3083.

Yoshida K. Coronoidotomy as treatment for trismus due to jaw-closing oromandibular dystonia. Mov Disord 2006; 21:1028–1031. https://doi.org/10.1002/mds.20859

Yoshida K. How do I inject botulinum toxin into the lateral and medial pterygoid muscles? Mov Disord Clin Pract 2017; 4:285. https://doi.org/10.1002/mdc3.12460

Yoshida K. Computer-aided design/computer-aided manufacturing-derived needle guide for injection of botulinum toxin into the lateral pterygoid muscle in patients with oromandibular dystonia. J Oral Facial Pain Headache. 2018 Spring;32(2):e13-e21. doi: 10.11607/ofph.1955

Yoshida K, Kaji R, Kubori T, Kohara N, Iizuka T, Kimura J. Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord. 1998; 13:699–705. https://doi.org/10.1002/mds.870130416

Yoshida K, Kaji R, Shibasaki H, Iizuka T. Factors influencing the therapeutic effect of muscle afferent block for oromandibular dystonia and dyskinesia: implications for their distinct pathophysiology. Int J Oral Maxillofac Surg 31:499–505. https://doi.org/10.1054/ijom.2002.0291

Yoshida K. Sensory trick splint as a multimodal therapy for oromandibular dystonia. J Prosthodont Res 2018; 62:239–244. https://doi. org/10.1016/j.jpor.2017.09.004

Yoshida K. Surgical intervention for oromandibular dystonia-related limited mouth opening: long-term follow-up. J Craniomaxillofac Surg 2017;45:56–62. https://doi.org/10.1016/j.jcms. 2016.10.009

Lo SE, Gelb M, Frucht SJ. Geste antagonistes in idiopathic lower cranial dystonia. Mov Disord 2007; 22:1012 7.

Singer C, Papapetropoulos S. A comparison of jaw closing and jaw opening idiopathic oromandibular dystonia. Parkinsonism Relat Disord 2006;12:115 8.

Poisson K, Thobois et al (2012) History of the “geste antagoniste” sign in cervical dystonia. J Neurol 259:1580–1584.

Bradnam L, Barry C. The role of the trigeminal sensory nuclear complex in the pathophysiology of Craniocervical dystonia. J Neurosci 2013; 33:18358–18367.

De Meyer M, Vereecke L, Bottenberg P, Jacquet W, Sims AB, Santens P. Oral appliances in the treatment of oromandibular dystonia: a systematic review. Acta Neurol Belg. 2020 Aug;120(4):831-836. doi: 10.1007/s13760-020-01404-4. Epub 2020 Jun 27

Verma SP, Sinha UK. Use of an oral sensory feedback device in the management of jaw-opening dystonia. Otolaryngol Head Neck Surg 2009;141:142-3.

Farag AM, Mier RW, Correa LP. Utilizing the concept of geste antagoniste for conservative management of oro-mandibular tardive dyskinesia: A case report and mini-review. Cranio 2016;34:338-42.

Schneider R, Hoffman HT. Oromandibular dystonia: A clinical report. J Prosthet Dent 2011;106:355-8.

Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long term follow up. Neurology 1999;53:2102 7.

Yoshida, K. Botulinum neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins 2018, 10, 174.

Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53:633–639. https:// doi. org/ 10. 1136/ jnnp. 53.8. 633

Van Den Bergh P, Francart J, Mourin S et al (1995) Five-year experience in the treatment of focal movement disorders with low-dose dysportTM botulinum toxin. Muscle Nerve 18:720– 729. https:// doi. org/ 10. 1002/ mus. 88018 0708

Brin MF, Fahn S, Moskowitz C et al (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2:237–254. https:// doi. org/ 10. 1002/ mds. 87002 0402

Ruiz-de-León-Hernández G, Díaz-Sánchez R-M, Torres-Lagares D et al (2018) Botulinum toxin A for patients with orofacial dystonia: prospective, observational, single-centre study. Int J Oral Maxillofac Surg 47:386–391. https:// doi. org/ 10. 1016/j. ijom. 2017. 11. 006

Moscovich M, Chen ZP, Rodriguez R (2015) Successful treatment of open jaw and jaw deviation dystonia with botulinum toxin using a simple intraoral approach. J Clin Neurosci 22:594– 596. https:// doi. org/ 10. 1016/j. jocn. 2014. 08. 027

Nastasi L, Mostile G, Nicoletti A et al (2016) Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol 263:1702–1708.

Ramirez Castaneda J, Jankovic J. Long term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20 year follow up. Toxicon 2014;90:344 8.

Posada IJ, Ramos A. Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Park Relat Disord 2011; 17:570–572

Mendes RA, Upton LG. Management of dystonia of the lateral pterygoid muscle with botulinum toxin A. Br J Oral Maxillofac Surg 2009; 47:481–483.

Møller E, Bakke M, Dalager T, Werdelin LM (2007) Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord 22:785–790.

Simpson DM, Hallett M, Ashman EJ et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and Headache Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86:1818–1826.

Simpson DM, Blitzer A, Brashear A et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurologysymbol. Neurology 2008; 70:1699–1706

Czyz CN, Burns JA, Petrie TP et al (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol. https:// doi. org/ 10. 1016/j. ajo. 2013. 02. 001

Hassell TJW, Charles D. Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins (Basel) 2020;12:269

Spiegel, L.L.; Ostrem, J.L.; Bledsoe, I.O. FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia. Toxins 2020, 12, 332.

Jankovic, J. Botulinum toxin: State of the art. Mov. Disord. 2017, 32, 1131–1138

Anandan, C.; Jankovic, J. Botulinum toxin in movement disorders: An update. Toxins 2021, 13, 42

Rossetto, O.; Pirazzini, M.; Montecucco, C. Botulinum neurotoxins: Genetic, structural and mechanistic insights. Nat. Rev.Microbiol. 2014, 12, 535549.

Pirazzini, M.; Rossetto, O.; Eleopra, R.; Montecucco, C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol. Rev. 2017, 69, 200235

Luvisetto, S. Botulinum neurotoxins in central nervous system: An overview from animal models to human therapy. Toxins 2021,13, 751. [CrossRef]

Giladi, N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J. Neurol. Sci. 1997, 152, 132135.

Hok P.; Veverka, T.; Hlustik, P.; Nevrly, M.; Kanovsky, P. The central effects of botulinum toxin in dystonia and spasticity. Toxins 2021, 13, 155

Weise D.; Weise C.M.; Naumann, M. Central effects of botulinum neurotoxin-Evidence from human studies. Toxins 2019, 11, 21.

Yoshida, K. Behandlungsstrategien bei oromandibulärer Dystonie. Fortschr. Neurol. Psychiatr. 2021, 89, 1562–1572.

Albrecht, P.; Jansen, A.; Lee, J.I.; Moll, M.; Ringelstein, M.; Rosenthal, D.; Bigalke, H.; Aktas, O.; Hartung, H.P.; Hefter, H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019, 92, E48–E54.

Jankovic, J.; Schwartz, K. Response and immuno resistance to botulinum toxin injections. Neurology 1995, 45, 1743–1746.

Brin, M.F.; Comella, C.L.; Jankovic, J.; Lai, F.; Naumann, M.; Ahmed, F.; Brashear, A.; Chehrenama, M.; Erjanti, H.; Evatt, M.; et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord. 2008, 23, 1353–1360.

Naumann, M.; Boo, L.M.; Ackerman, A.H.; Gallagher, C.J. Immunogenicity of botulinum toxins. J. Neural Transm. 2013, 120, 275–290.

Blitzer, A.; Brin, M.; Greene, P.E.; Fahn, S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol. Rhinol. Laryngol. 1989, 98, 93–97.

C. Clemente, Muscles and fasciae, in: C. Clemente (Ed.), Gray’s Anatomy, Lea & Feabiger, Philadelphia, 1984.

Yoshida, K. Clinical application of botulinum neurotoxin for diseases in the stomatognathic system. J. Jpn. Dent. Soc. Anesthesiol. 2020, 48, 33–40.

Yoshida K. Clinical and phenomelogical characteristics of patients with task-specific lingual dystonia: Possible association with occupation. Front. Neurol. 2017, 8, 649

Berkovitz B.K.B. Tongue. In Gray’s Anatomy, 41st ed.; Standring, S., Ed.; Elsevier: Amsterdam, The Netherlands, 2016; pp. 511–517

Yoshida K. Botulinum neurotoxin therapy for lingual dystonia using an individualized injection method based on clinical features. Toxins 2019, 11, 51

Yoshida K. Clinical characteristics of functional movement disorders in the stomatognathic system. Front. Neurol. 2020, 11, 23.

Ghang, J.Y.; Lee, M.K.; Jun, S.M.; Ghang, C.G. Outcome of pallidal deep brain stimulation in Meige syndrome. J. Korean Neurosurg.Soc. 2010, 48, 134–138. [CrossRef] [PubMed]

Lyons, M.K.; Birch, B.D.; Hillman, R.A.; Boucher, O.K.; Evidente, V.G. Long-term follow-up of deep brain stimulation for Meige syndrome. Neurosurg. Focus 2010, 29, E5.

Ostrem, J.L.; Marks, W.J.; Volz, M.M.; Heath, S.L.; Starr, P.A. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov. Disord. 2007, 22, 1885–1891.

Cury, R.G.; Kalia, S.K.; Shah, B.B.; Jimenez-Shahed, J.; Prashanth, L.K.; Moro, E. Surgical treatment of dystonia. Expert Rev. Neurother. 2018, 18, 477–492. [CrossRef] [PubMed]

Kupsch, A.; Benecke, R.; Müller, J.; Trottenberg, T.; Schneider, G.H.; Poewe, W.; Eisner, W.; Wolters, A.; Müller, J.U.; Deuschl, G.; et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N. Engl. J. Med. 2006, 355, 1978–1990.

Tagliati, M.; Krack, P.; Volkmann, J.; Aziz, T.; Krauss, J.K.; Kupsch, A.; Vidailhet, A.M. Long-term management of DBS in dystonia: Response to stimulation, adverse events, battery changes, and special considerations. Mov. Disord. 2011, 26 (Suppl. S1), S54–S62